48Hour Discovery Accepted into Johnson & Johnson Innovation—JLABS

October 18, 2023 02:00 AM AEDT | By EIN Presswire

Google News:

48Hour Discovery Accepted into Johnson & Johnson Innovation—JLABS — Image source: EIN Presswire

Recent News

AEG Celebrates the LGBTQIA + Community at the 2025 LA Pride Parade

What happens if AI can do everything better than humans?

Brookfield Infrastructure reportedly acquiring Hotwire for $7 billion

Nvidia GTC Paris is ’another bullish proof point’ long term - Morgan S...

EDMONTON, ALBERTA, CANADA, October 17, 2023 /EINPresswire.com/ -- 48Hour Discovery Inc., a leading biotech company focused on peptide drug discovery for targeted radiopharmaceuticals, announced today that it has been accepted into Johnson & Johnson Innovation—JLABS (JLABS) Toronto-based incubator program.

“We are thrilled to be accepted into JLABS and are excited to have access to their world-class resources and network,” said Rick Finnegan, CEO of 48Hour Discovery. “This is a great opportunity for us to accelerate our development efforts and to collaborate with other innovative companies and experts in the field.”

JLABS is the global incubator network of Johnson & Johnson Innovation LLC and provides early-stage innovators with access to capital-efficient lab space and resources, including mentorship, community, industry connections and entrepreneurial programs.

48Hour Discovery’s mission is to rapidly advance the field of nuclear medicine leveraging its proprietary drug discovery platform. The company is accelerating its research and development efforts and moving closer to bringing its cutting-edge technology to patients in need.

Targeted radiopharmaceuticals are a cutting-edge class of drugs that combine the precision of molecular targeting with the power of radioisotopes to deliver highly effective treatments and diagnostics for cancer and other diseases. This offers a promising alternative to conventional chemotherapy and radiation therapy, which can damage healthy tissue and cause serious side effects.

“From access to radioisotopes, to excellence in clinical trials, Edmonton has the building blocks to support the development of this exciting new class of therapeutics with the potential to radically improve patient lives,” said Finnegan. “Our technology is the perfect fit to bring this ecosystem together, to unlock the massive potential in our backyard”.

The company kickstarted internal discovery campaigns against several clinically validated cancer targets with funding they received as winners of the Startup TNT Investment Summit VI in late 2022.

About 48Hour Discovery
48Hour Discovery is a dynamic peptide discovery platform that has revolutionized drug discovery through its innovative approaches to peptide design. Leveraging cutting-edge technologies, the platform accelerates the identification and optimization of peptides with therapeutic potential, offering a novel pathway to addressing unmet medical needs. Established in 2017, the company has validated its technology platform securing partnerships with over 20 companies including global pharma and leaders in the radiopharmaceutical industry. For more information, visit. For more information, visit www.48hourdiscovery.com

Adam Brown
48Hour Discovery
email us here
Visit us on social media:
LinkedIn

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.